The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Mironova Yu.S.

Siberian State Medical University, Tomsk, Russia

Zhukova N.G.

Siberian State Medical University, Tomsk, Russia

Zhukova I.A.

Siberian State Medical University, Tomsk

Alifirova V.M.

Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Tomsk, Russia

Izhboldina O.P.

Siberian State Medical University, Tomsk

Latypova A.V.

Siberian State Medical University, Tomsk, Russia

Parkinson’s disease and glutamatergic system

Authors:

Mironova Yu.S., Zhukova N.G., Zhukova I.A., Alifirova V.M., Izhboldina O.P., Latypova A.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(5): 138‑142

DOI: 10.17116/jnevro201811851138

Views: 4922

Downloaded: 128

Download PDF (RU)
Contact the author
Table of contents

PARKINSON’S DISEASE AND GLUTAMATERGIC SYSTEM
PARKINSON’S DISEASE AND GLUTAMATERGIC SYSTEM

To cite this article:

Mironova YuS, Zhukova NG, Zhukova IA, Alifirova VM, Izhboldina OP, Latypova AV. Parkinson’s disease and glutamatergic system. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(5):138‑142. (In Russ.)
https://doi.org/10.17116/jnevro201811851138

 
Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Tremor-dominant form of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):28-35
Nocturia in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):48-54
Asso­ciations of serum neuromarkers with clinical features of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):145-152
Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):22-30
The asso­ciation of single-nucleotide poly­morphism rs6265 of the brain-derived neurotrophic factor gene with clinical features in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):82-88
Sarcopenia as a non-motor symptom of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):15-22
Asso­ciation of inflammation and chro­nic fati­gue syndrome in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):79-87
Electric acti­vity of the brain at early and late clinical stages of expe­rimental mode­ling of Parkinson’s disease, an impact of hema­ntane. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):129-134
Diagnosis and treatment approaches for sialorrhea in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):29-34
Problems in orga­nizing neurosurgical care for patients with Parkinson’s disease in the Russian Fede­ration. Burdenko's Journal of Neurosurgery. 2024;(3):5-13

Clinical variants of Parkinson’s disease (PD) are not restricted to motor symptoms but include a wide spectrum of different non-motor symptoms: cognitive, psychotic, autonomic and sensory. These non-motor symptoms often occur long before classical motor features. Associated pathologic changes can now be identified at earliest stages using neuroimaging, pathomorphological and genetic studies. Therefore, PD is currently considered as a multifactorial, heterogenic systemic disease associated with involvement of multiple neurotransmitter systems. This leads to understanding that not only dopaminergic but also other neurotransmitter systems, including glutamatergic system, are involved in the pathogenesis of PD. This article aimed at investigating a role of glutamatergic system in the initiation of neurodegenerative process. The role of glutamate as a neurotransmitter and a neurotoxin in the pathogenesis of PD and progression of its clinical manifestations is discussed. The authors suggest that research into glutamate excitotoxicity in PD patients might allow the improvement of treatment tactics and correction of pathogenetic therapy.

Keywords:

Parkinson’s disease
glutamate
excitotoxicity

Authors:

Mironova Yu.S.

Siberian State Medical University, Tomsk, Russia

Zhukova N.G.

Siberian State Medical University, Tomsk, Russia

Zhukova I.A.

Siberian State Medical University, Tomsk

Alifirova V.M.

Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Tomsk, Russia

Izhboldina O.P.

Siberian State Medical University, Tomsk

Latypova A.V.

Siberian State Medical University, Tomsk, Russia

List of references:

  1. Freitas ME, Fox SH. Nondopaminergic treatments for Parkinson’s disease: current and future prospects. 2016. https://doi.org/10.2217/nmt-2016-0005
  2. Braak H, Del Tredici K, Rüb U, De Vos RA, Steur ENJ, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging. 2003;24(2):197-211. https://doi.org/10.1016/s0197-4580(02)00065-9
  3. Illarioshkin SN, Slominskij PA, Ivanova-Smolenskaja IA, Bagyeva GH, Zagorovskaja TB, Polevaja EV, Shadrina MI, Fedorova NV, Limborskaja SA. Geneticheskaja geterogennost’ pervichnogo parkinsonizma. Red. Illarioshkina S.N., Jahno N.N. Bolezn’ Parkinsona i rasstrojstva dvizhenij. Rukovodstvo dlja vrachej. M; 2008. (In Russ.)
  4. Lee FJ, Liu F. Genetic factors involved in the pathogenesis of Parkinson’s disease. Brain Research Reviews. 2008;58(2):354-364. https://doi.org/10.1016/j.brainresrev.2008.02.001
  5. Novikova L, Garris B, Garris D, Lau Y-S. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine/probenecid model of Parkinson’s disease. Neuroscience. 2006;140(1):67-76. https://doi.org/10.1016/j.neuroscience.2006.02.007
  6. Ambrosi G, Cerri S, Blandini F. A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease. Journal of Neural Transmission. 2014;121(8):849-859. https://doi.org/10.1007/s00702-013-1149-z
  7. Himmelberg MM, West RJ, Elliott CJ, Wade AR. Abnormal visual gain control and excitotoxicity in early-onset Parkinson’s disease Drosophila models. Journal Neurophysiol. 2017;jn-00681. https://doi.org/10.1152/jn.00681.2017
  8. Morales I, Sabate M, Rodriguez M. Striatal glutamate induces retrograde excitotoxicity and neuronal degeneration of intralaminar thalamic nuclei: their potential relevance for Parkinson’s disease. European Journal of Neuroscience. 2013;38(1):2172-2182. https://doi.org/10.1111/ejn.12205
  9. Meldrum BS. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. The Journal of Nutrition. 2000;130(4):1007-1015.
  10. Plimmer RHA. The chemical constitution of the proteins. By R.H. Aders Plimmer. 1908. https://doi.org/10.5962/bhl.title.21068
  11. Sano C. History of glutamate production. American Journal of Clinical Nutrition. 2009;90(3):728-732. https://doi.org/10.3945/ajcn.2009.27462f
  12. Lucas D, Newhouse J. The toxic effect of sodium L-glutamate on the inner layers of the retina. Archives of Ophthalmology. 1957;58(2):193-201. https://doi.org/10.1001/archopht.1957.00940010205006
  13. Olney JW. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science. 1969;164(3880):719-721. https://doi.org/10.1126/science.164.3880.719
  14. Olney JW, Sharpe LG. Brain lesions in an infant rhesus monkey treated with monosodium glutamate. Science. 1969;166(3903):386-388. https://doi.org/10.1126/science.166.3903.386
  15. Jørgensen MB, Diemer NH. Selective neuron loss after cerebral ischemia in the rat: possible role of transmitter glutamate. Acta Neurologica Scandinavica. 1982;66(5):536-546. https://doi.org/10.1111/j.1600-0404.1982.tb03140.x
  16. Rothman S. Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death. The Journal of Neuroscience. 1984;4(7):1884-1891.
  17. Petkova AT, Leapman RD, Guo Z, Yau W-M, Mattson MP, Tycko R. Self-propagating, molecular-level polymorphism in Alzheimer’s ß-amyloid fibrils. Science. 2005;307(5707):262-265. https://doi.org/10.1126/science.1105850
  18. Mattson MP, Lee RE, Adams ME, Guthrie PB, Kater S. Interactions between entorhinal axons and target hippocampal neurons: a role for glutamate in the development of hippocampal circuitry. Neuron. 1988;1(9):865-876. https://doi.org/10.1016/0896-6273(88)90134-1
  19. Boldyrev AA, Eshhenko ND, Iljuha VA, Kjajvjarjajnen EI. Nejrohimija. Pod red. Vladimirov Ju.A. V uchebnom posobii dlja vuzov. M.: Drofa; 2010. (In Russ.)
  20. Domercq M, Etxebarria E, Pérez‐Samartín A, Matute C. Excitotoxic oligodendrocyte death and axonal damage induced by glutamate transporter inhibition. Glia. 2005;52(1):36-46. https://doi.org/10.1002/glia.20221
  21. Dunah AW, Yasuda RP, Luo J, Wang Y, Prybylowski KL, Wolfe BB. Biochemical studies of the structure and function of theN-methyl-D-aspartate subtype of glutamate receptors. Molecular Neurobiology. 1999;19(2):151-179. https://doi.org/10.1007/bf02743658
  22. Herges K, Millward JM, Hentschel N, Infante-Duarte C, Aktas O, Zipp F. Neuroprotective effect of combination therapy of glatiramer acetate and epigallocatechin-3-gallate in neuroinflammation. PloS One. 2011;6(10): 25456. https://doi.org/10.1371/journal.pone.0025456
  23. McKenna MC, Waagepetersen HS, Schousboe A, Sonnewald U. Neuronal and astrocytic shuttle mechanisms for cytosolic-mitochondrial transfer of reducing equivalents: current evidence and pharmacological tools. Biochemical Pharmacology. 2006;71(4):399-407. https://doi.org/10.1016/j.bcp.2005.10.011
  24. O’shea RD, Fodera MV, Apricó K, Dehnes Y, Danbolt NC, Crawford D, Beart PM. Evaluation of drugs acting at glutamate transporters in organotypic hippocampal cultures: new evidence on substrates and blockers in excitotoxicity. Neurochemical Research. 2002;27(1):5-13. https://doi.org/110.1023/a:1014813518604
  25. Bonde C, Sarup A, Schousboe A, Gegelashvili G, Zimmer J, Noraberg J. Neurotoxic and neuroprotective effects of the glutamate transporter inhibitor DL-threo-beta-benzyloxyaspartate (DL-TBOA) during physiological and ischemia-like conditions. Neurochemistry International. 2003;43(4):371-380. https://doi.org/10.1016/s0197-0186(03)00024-x
  26. Beart P, O’shea R. Transporters for L‐glutamate: An update on their molecular pharmacology and pathological involvement. British Journal of Pharmacology. 2009;150(1):5-17. https://doi.org/10.1038/sj.bjp.0706949
  27. Laube B, Kuhse J, Betz H. Evidence for a tetrameric structure of recombinant NMDA receptors. Journal of Neuroscience. 1998;18(8):2954-2961.
  28. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry. 2000;47(4):351-354. https://doi.org/10.1016/s0006-3223(99)00230-9
  29. Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflügers Archiv — European Journal of Physiology. 2010;460(2):525-542. https://doi.org/10.1007/s00424-010-0809-1
  30. BEhe P, Stern P, Wyllie DJ, Nassar M, Schoepfer R, Colquhoun D. Determination of NMDA NR1 subunit copy number in recombinant NMDA receptors. Proceedings of the Royal Society B: Biological Sciences. 1995;262(1364):205-213. https://doi.org/10.1098/rspb.1995.0197
  31. Nicoletti F, Bockaert J, Collingridge GL, Conn PJ, Ferraguti F, Schoepp DD, Wroblewski JT, Pin JP. Metabotropic glutamate receptors: From the workbench to the bedside. Neuropharmacology. 2011;60(7):1017-1041. https://doi.org/10.1016/j.neuropharm.2010.10.022
  32. Duncan JR, Lawrence AJ. The role of metabotropic glutamate receptors in addiction: Evidence from preclinical models. Pharmacology Biochemistry and Behavior. 2012;100(4):811-824. https://doi.org/10.1016/j.pbb.2011.03.015
  33. Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nature Reviews Neuroscience. 2013;14(6):383-3400. https://doi.org/10.1038/nrn3504
  34. Cull-Candy S, Brickley S, Farrant M. NMDA receptor subunits: diversity, development and disease. Current Opinion in Neurobiology. 2001;11(3):327-335. https://doi.org/10.1016/s0959-4388(00)00215-4
  35. Iwayama-Shigeno Y, Yamada K, Itokawa M, Toyota T, Meerabux JM, Minabe Y, Mori N, Inada T, Yoshikawa T. Extended analyses support the association of a functional (GT) n polymorphism in the GRIN2A promoter with Japanese schizophrenia. Neuroscience Letters. 2005;378(2):102-105. https://doi.org/10.1016/j.neulet.2004.12.013
  36. Loftis JM, Janowsky A. The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacology & Therapeutics. 2003;97(1):55-585. https://doi.org/10.1016/s0163-7258(02)00302-9
  37. Bredt DS, Nicoll RA. AMPA receptor trafficking at excitatory synapses. Neuron. 2003;40(2):361-379. https://doi.org/10.1016/s0896-6273(03)00640-8
  38. Furuyama T, Kiyama H, Sato K, Park HT, Maeno H, Takagi H, Tohyama M. Region-specific expression of subunits of ionotropic glutamate receptors (AMPA-type, KA-type and NMDA receptors) in the rat spinal cord with special reference to nociception. Molecular Brain Research. 1993;18(1):141-151. https://doi.org/10.1016/0169-328x(93)90183-p
  39. Danysz W, Parsons C, Quack G. NMDA channel blockers: memantine and amino-aklylcyclohexanes — in vivo characterization. Amino Acids. 2000;19(1):167-172. https://doi.org/10.1007/s007260070045
  40. Moratalla R, Khairnar A, Simola N, Granado N, García-Montes JR, Porceddu PF, Tizabi Y, Costa G, Morelli M. Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms. Progress in Neurobiology. 2017;155(suppl C):149-170. https://doi.org/10.1016/j.pneurobio.2015.09.011
  41. Granado N, Ares-Santos S, Moratalla R. Methamphetamine and Parkinson’s disease. Parkinson’s Disease. 2013;1-10. https://doi.org/10.1155/2013/308052
  42. Fundytus ME. Glutamate receptors and nociception. CNS Drugs. 2001;15(1):29-58. https://doi.org/10.2165/00023210-200115010-00004
  43. From Neuron to Brain. Fifth Edition. By John G. Nicholls, A. Robert Martin, Paul A. Fuchs, David A. Brown, Mathew E. Diamond, and David A. Weisblat. Sunderland (Massachusetts): Sinauer Associates. The Quarterly Review of Biology. 2012;87(2):158-158. https://doi.org/10.1086/665489
  44. Perrella J, Bhavnani BR. Protection of cortical cells by equine estrogens against glutamate-induced excitotoxicity is mediated through a calcium independent mechanism. BMC Neuroscience. 2005;6(1):34. https://doi.org/10.1186/1471-2202-6-34
  45. Fogal B, Trettel J, Uliasz T, Levine E, Hewett S. Changes in secondary glutamate release underlie the developmental regulation of excitotoxic neuronal cell death. Neuroscience. 2005;132(4):929-942. https://doi.org/10.1016/j.neuroscience.2005.01.036
  46. Maragakis NJ, Rothstein JD. Glutamate transporters in neurologic disease. Archives of Neurology. 2001;58(3):365-370. https://doi.org/10.1001/archneur.58.3.365
  47. Szydlowska K, Tymianski M. Calcium, ischemia and excitotoxicity. Cell Calcium. 2010;47(2):122-129. https://doi.org/10.1016/j.ceca.2010.01.003
  48. Yatomi Y, Tanaka R, Shimura H, Miyamoto N, Yamashiro K, Takanashi M, Urabe T, Hattori N. Chronic brain ischemia induces the expression of glial glutamate transporter EAAT2 in subcortical white matter. Neuroscience. 2013;244:113-121. https://doi.org/10.1016/j.neuroscience.2013.04.018
  49. Ionov ID. Self-amplification of nigral degeneration in Parkinson’s disease: a hypothesis. International Journal of Neuroscience. 2008;118(12):1741-1758. https://doi.org/10.1080/00207450802330561
  50. Tovar KR, Westbrook GL. Mobile NMDA receptors at hippocampal synapses. Neuron. 2002;34(2):255-264. https://doi.org/10.1016/s0896-6273(02)00658-x
  51. Assous M, Had-Aissouni L, Gubellini P, Melon C, Nafia I, Salin P, Kerkerian-Le-Goff L, Kachidian P. Progressive Parkinsonism by acute dysfunction of excitatory amino acid transporters in the rat substantia nigra. Neurobiology of Disease. 2014;65:69-81. https://doi.org/10.1016/j.nbd.2014.01.011
  52. Gorman AM. Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling. Journal of Cellular and Molecular Medicine. 2008;12(6a):2263-2280. https://doi.org/10.1111/j.1582-4934.2008.00402.x
  53. Zhou X, Chen Z, Yun W, Ren J, Li C, Wang H. Extrasynaptic NMDA receptor in excitotoxicity: function revisited. The Neuroscientist. 2014;21(4): 337-344. https://doi.org/10.1177/1073858414548724
  54. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller J, Storey E, Srivastava R, Rosen B, Hyman B. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. Journal of Neuroscience. 1993;13(10):4181-4192.
  55. Henneberry RC. The role of neuronal energy in the neurotoxicity of excitatory amino acids. Neurobiology of Aging. 1989;10(5):611-613. https://doi.org/10.1016/0197-4580(89)90149-8
  56. Zeevalk GD, Nicklas WJ. Chemically induced hypoglycemia and anoxia: relationship to glutamate receptor-mediated toxicity in retina. Journal of Pharmacology and Experimental Therapeutics. 1990;253(3):1285-1292.
  57. Harkany T, Abraham I, Timmerman W, Laskay G, Toth B, Sasvari M, Konya C, Sebens J, Korf J, Nyakas C. β‐Amyloid neurotoxicity is mediated by a glutamate‐triggered excitotoxic cascade in rat nucleus basalis. European Journal of Neuroscience. 2000;12(8):2735-2745. https://doi.org/110.1046/j.1460-9568.2000.00164.x
  58. Ji R-R, Kohno T, Moore KA, Woolf CJ. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends in Neurosciences. 2003;26(12):696-705. https://doi.org/10.1016/j.tins.2003.09.017
  59. Greenamyre JT, Porter RH. Anatomy and physiology of glutamate in the CNS. Neurology. 1994;44(11 suppl 8):7-13.
  60. Dunah AW, Wang Y, Yasuda RP, Kameyama K, Huganir RL, Wolfe BB, Standaert DG. Alterations in subunit expression, composition, and phosphorylation of striataln-methyl-d-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson’s disease. Molecular Pharmacology. 2000;57(2):342-352.
  61. Klockgether T, Turski L. NMDA antagonists potentiate antiparkinsonian actions of L‐dopa in monoamine‐depleted rats. Annals of Neurology. 1990;28(4):539-546. https://doi.org/10.1002/ana.410280411
  62. Lange KW, Kornhuber J, Riederer P. Dopamine/glutamate interactions in Parkinson’s disease. Neuroscience & Biobehavioral Reviews. 1997;21(4):393-400. https://doi.org/10.1016/s0149-7634(96)00043-7
  63. Lindefors N, Ungerstedt U. Bilateral regulation of glutamate tissue and extracellular levels in caudate-putamen by midbrain dopamine neurons. Neuroscience Letters. 1990;115(2):248-252. https://doi.org/10.1016/0304-3940(90)90463-j

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.